Abstract:Abstract Glutamine catabolism has been shown to be critical in many cancer types, particularly in MYC dependent tumor types. Given that MYC dependent cell lines have been shown to be dependent on glutamine for growth and survival, we hypothesize that inhibiting glutamine metabolism could slow the growth of MYC driven tumors in vivo. Small molecule (BPTES) inhibition of kidney-type glutaminase (GLS) is being developed as an anti-cancer therapy, yet basic questions remained unanswered about glutamine inhibition. The BPTES insensitive liver-type glutaminase (GLS2) has been proposed to act as a tumor suppressor in liver cancer cell lines. We have found that hepatocellular carcinomas downregulate GLS2 and upregulate GLS compared to surrounding tissue in both humans and mice, leaving hepatocellular carcinomas potentially sensitive to GLS inhibition. BPTES slows the growth of hepatocellular carcinoma cell lines in vitro. Here were report the first study that demonstrates the ability of BPTES to slow tumor progression in genetic cancer models in immunocompetent mice, showing the BPTES prolongs survival of mice in a MYC driven hepatocellular carcinoma model. However, we could not determine from these data if the anti-cancer effects of GLS inhibition in vivo were systemic or cell autonomous, causing us to switch to a xenograft system. Using prostate and lymphoma cell lines overexpressing the BPTES resistant GLS K325A mutant, we show that BPTES functions through on-target inhibition of GLS in vitro. We then used a p493-6 B-cell lymphoma cell line to determine the cell autonomous effects of BPTES in vivo. P493-6 xenograft growth was slowed by BPTES treatment, while p493 xenografts overexpressing either wild type GLS or BPTES resistant GLS K325A were not slowed by BPTES treatment in vivo. We then set out to develop an alternative method to perform tumor specific knock down GLS in vivo to obtain genetic evidence of the role of GLS in tumor cells, developing a human specific vivo-morpholino that targets GLS for nonsense-mediated decay. Consistent with the effect of BPTES on tumor cells, the human GLS targeting vivo-morpholino slowed p493-6 xenograft growth in vivo. As the vivo-morpholino knockdown of GLS was xenograft specific, it demonstrates that GLS inhibition slows cancer growth through cancer cell autonomous methods and not though systemic changes that alter the tumor niche. In summary, we find that BPTES exhibits on target GLS inhibition in vivo to prolong survival in mouse hepatocellular carcinoma mouse models. Citation Format: Zachary Stine, Yan Xiang, Jinsong Xia, Ping Gao, Ramani Dinavahi, Chi V. Dang. Inhibition of glutaminase induces slows tumor growth cell autonomously and promotes survival in a MYC driven hepatocellular carcinoma mouse model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2957. doi:10.1158/1538-7445.AM2014-2957

Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathwayResearch in context

Targeting Glutaminase 1 Attenuates Stemness Properties in Hepatocellular Carcinoma by Increasing Reactive Oxygen Species and Suppressing Wnt/beta-catenin Pathway

GLUT-1 Sirna Enhances Radiosensitization of Laryngeal Cancer Stem Cells Via Enhanced DNA Damage, Cell Cycle Redistribution, and Promotion of Apoptosis in Vitro and in Vivo.

Effect of GLUT1 Inhibition and Autophagy Modulation on the Growth and Migration of Laryngeal Carcinoma Stem Cells under Hypoxic and Low-Glucose Conditions

Shrna Glut-1 Inhibits Cell Viability, Apoptosis and Migration of Laryngeal Carcinoma HEp-2 Cells Through Regulating Beclin-1-mediated Autophagy

Effects of GLS1 on the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma in Vitro and in Vivo

Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma

Targeting mTORC2/HDAC3 Inhibits Stemness of Liver Cancer Cells Against Glutamine Starvation

Loss of MiR-192-5p Initiates a Hyperglycolysis and Stemness Positive Feedback in Hepatocellular Carcinoma.

Glutaminase Sustains Cell Survival Via the Regulation of Glycolysis and Glutaminolysis in Colorectal Cancer.

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Regulation of stem-like cancer cells by glutamine through β-catenin pathway mediated by redox signaling

Glutamine synthetase and hepatocellular carcinoma

Therapeutic Targeting of the GLS1-c-Myc Positive Feedback Loop Suppresses Glutaminolysis and Inhibits Progression of Head and Neck Cancer

Targeting GLS1 to cancer therapy through glutamine metabolism

Glutamate dehydrogenase 1 mediated glutaminolysis sustains HCC cells survival under glucose deprivation

Abstract 2957: Inhibition of Glutaminase Induces Slows Tumor Growth Cell Autonomously and Promotes Survival in a MYC Driven Hepatocellular Carcinoma Mouse Model

Promotion of hepatocellular carcinoma stemness and progression by abnormal spindle-like microcephaly-associated protein via the Wnt/β-catenin pathway

GLUD1 inhibits hepatocellular carcinoma progression via ROS-mediated p38/JNK MAPK pathway activation and mitochondrial apoptosis

GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors

OGDHL Silencing Promotes Hepatocellular Carcinoma by Reprogramming Glutamine Metabolism.